Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

Groot, S. de; Charehbili, A.; Laarhoven, H.W.M. van; Mooyaart, A.L.; Dekker-Ensink, N.G.; Ven, S. van de; ... ; Dutch Breast Canc Res Grp (2016)

Article / Letter to editor

• Breast cancer
• Neoadjuvant chemotherapy
• Glucose
• Insulin
• IGF-1
• IGF-BP3
• IGF-1R
• Miller and Payne
• Pathological complete response
• Single nucleotide polymorphisms

• All authors: Groot, S. de; Charehbili, A.; Laarhoven, H.W.M. van; Mooyaart, A.L.; Dekker-Ensink, N.G.; Ven, S. van de; Janssen, L.G.M.; Swen, J.J.; Smit, V.T.H.B.M.; Heijns, J.B.; Kessels, L.W.; Straaten, T. van der; Bohringer, S.; Gelderblom, H.; Hoeven, J.J.M. van der; Guchelaar, H.J.; Pijl, H.; Kroep, J.R.; Dutch Breast Canc Res Grp
• Date: 2016-01-06
• Journal: Breast Cancer Research
• Volume: 18
• DOI: doi:10.1186/s13058-015-0663-3